Jerome B Zeldis
CIK 1433982 · Executive VP of Research & Dev · last filed 2026-10-13
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
PTCT price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SCOTTSDALE, AZ 85258
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SNGX | Director | — | $0.35 | — | $0 | 6 | 2026-10-13 |
| PTCT | Director | 22,500 | $61.07 | $1.37M | -$2.00M | 15 | 2026-01-06 |
| NXGLW | Director | 106,664 | $0.01 | $1.2K | $106.6K | 8 | 2025-06-27 |
| NexImmune, Inc. (NEXI) Delisted | Executive VP of Research & Dev | 235 | $0.00 | $0 | $100.0K | 3 | 2022-04-07 |
| SOLIGENIX, INC. (SNGXW) Delisted | Director | 25,917 | $0.01 | $233 | $12.8K | 9 | 2021-09-24 |
| Streamex Corp. (BSGM) Delisted | Director | 10,794 | $6.35 | $68.5K | $10.5K | 5 | 2020-07-15 |
| Sorrento Therapeutics, Inc. (SRNE) Delisted | See Remarks | 10,000 | $0.00 | $5 | $51.5K | 4 | 2018-11-27 |
| Alliqua BioMedical, Inc. (ALQA) Delisted | Director | 131,125 | — | — | $240.7K | 8 | 2017-07-03 |
Recent Filings · Page 2 of 9
81 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-09-17 | NXGLW | Grant (A) | — | $0 | EDGAR |
| 2024-08-27 | NXGLW | Mixed | +10,000 | $25.0K | EDGAR |
| 2024-05-24 | PTCT | Mixed | — | -$236.4K | EDGAR |
| 2024-05-22 | PTCT | Notice (144) | −20,000 | -$764.8K | EDGAR |
| 2024-02-16 | PTCT | Grant (A) | +4,000 | $0 | EDGAR |
| 2023-12-15 | SNGX | Grant (A) | — | $0 | EDGAR |
| 2023-08-21 | NXGLW | Grant (A) | — | $0 | EDGAR |
| 2023-05-30 | NXGLW | Buy (P) | +5,000 | $11.7K | EDGAR |
| 2023-01-09 | PTCT | Grant (A) | +4,000 | $0 | EDGAR |
| 2022-11-21 | SNGX | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.